Nothing Special   »   [go: up one dir, main page]

SG11201705264WA - Novel multivalent nanoparticle-based vaccines - Google Patents

Novel multivalent nanoparticle-based vaccines

Info

Publication number
SG11201705264WA
SG11201705264WA SG11201705264WA SG11201705264WA SG11201705264WA SG 11201705264W A SG11201705264W A SG 11201705264WA SG 11201705264W A SG11201705264W A SG 11201705264WA SG 11201705264W A SG11201705264W A SG 11201705264WA SG 11201705264W A SG11201705264W A SG 11201705264WA
Authority
SG
Singapore
Prior art keywords
based vaccines
novel multivalent
multivalent nanoparticle
nanoparticle
novel
Prior art date
Application number
SG11201705264WA
Inventor
Barney S Graham
Masaru Kanekiyo
Hadi M Yassine
Original Assignee
The Usa As Represented By The Secretary Detp Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Usa As Represented By The Secretary Detp Of Health And Human Services filed Critical The Usa As Represented By The Secretary Detp Of Health And Human Services
Publication of SG11201705264WA publication Critical patent/SG11201705264WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
SG11201705264WA 2014-12-31 2015-12-31 Novel multivalent nanoparticle-based vaccines SG11201705264WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462098755P 2014-12-31 2014-12-31
PCT/US2015/068272 WO2016109792A2 (en) 2014-12-31 2015-12-31 Novel multivalent nanoparticle-based vaccines

Publications (1)

Publication Number Publication Date
SG11201705264WA true SG11201705264WA (en) 2017-07-28

Family

ID=55168477

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201705264WA SG11201705264WA (en) 2014-12-31 2015-12-31 Novel multivalent nanoparticle-based vaccines

Country Status (11)

Country Link
US (3) US11191727B2 (en)
EP (1) EP3240567A2 (en)
JP (3) JP6655623B2 (en)
KR (1) KR102713707B1 (en)
CN (1) CN107427571A (en)
AU (3) AU2015373928B2 (en)
BR (1) BR112017014219A2 (en)
CA (1) CA2974346A1 (en)
IL (2) IL294189B1 (en)
SG (1) SG11201705264WA (en)
WO (1) WO2016109792A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2705301C2 (en) 2012-02-16 2019-11-06 Влп Терапьютикс, Ллк Virus-like particles composition
TWI676636B (en) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 Virus like particle comprising pd-1 antigen or pd-1 ligand antigen
WO2015054639A1 (en) 2013-10-11 2015-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epstein-barr virus vaccines
EP3177720B1 (en) * 2014-08-08 2021-09-22 VLP Therapeutics, Inc. Virus like particle comprising modified envelope protein e3
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
US10098943B2 (en) 2014-09-11 2018-10-16 Vlp Therapeutics, Llc Flavivirus virus like particle
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
SG11201705264WA (en) * 2014-12-31 2017-07-28 The Usa As Represented By The Secretary Detp Of Health And Human Services Novel multivalent nanoparticle-based vaccines
MA46023A (en) * 2015-10-22 2019-07-03 Modernatx Inc BROAD SPECTRUM INFLUENZA VACCINE
PT3386484T (en) 2015-12-10 2022-08-01 Modernatx Inc Compositions and methods for delivery of therapeutic agents
IL303650B1 (en) 2016-09-02 2024-10-01 Us Health Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
EP3939604A3 (en) * 2016-10-21 2022-06-22 Merck Sharp & Dohme Corp. Influenza hemagglutinin protein vaccines
US10925958B2 (en) 2016-11-11 2021-02-23 Modernatx, Inc. Influenza vaccine
CN108148758B (en) * 2016-12-05 2021-09-17 中国科学院大连化学物理研究所 In-vitro model establishment method for extravillous trophoblast nanoparticle exposure
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
CN110603262A (en) 2017-04-04 2019-12-20 华盛顿大学 Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and uses thereof
US20200179532A1 (en) 2017-08-04 2020-06-11 The Hospital For Sick Children Nanoparticle platform for antibody and vaccine delivery
CA3070468A1 (en) 2017-09-01 2019-03-07 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to bcma and taci antigens for treatment of cancer
JP7403733B2 (en) 2017-09-04 2023-12-25 国立感染症研究所長 Method for manufacturing influenza HA split vaccine
AU2018388102A1 (en) 2017-12-21 2020-07-16 Green Biomed, Inc. Cross-immunizing antigen vaccine and method for preparation thereof
WO2019169120A1 (en) 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines
CN112512566A (en) 2018-04-03 2021-03-16 赛诺菲 Antigenic epstein-barr virus polypeptides
WO2020022272A1 (en) 2018-07-23 2020-01-30 公益財団法人ヒューマンサイエンス振興財団 Composition containing influenza vaccine
WO2020030654A1 (en) * 2018-08-07 2020-02-13 ETH Zürich Polypeptides self-assembling into nanoparticles
KR102076917B1 (en) * 2018-10-25 2020-02-13 연세대학교 산학협력단 Expression vector system for preparing recombinant self-assembled nanoparticles, and method of using the same
CN113423718A (en) * 2019-02-08 2021-09-21 美国政府(由卫生和人类服务部的部长所代表) Nanoparticle-based influenza virus vaccines and uses thereof
TWI776048B (en) * 2019-04-25 2022-09-01 財團法人農業科技研究院 Recombinant protein for preventing swine fever virus infection and composition and cell comprising the same.
CN110354271A (en) * 2019-05-21 2019-10-22 广州市妇女儿童医疗中心 One kind is based on including peptide-mediated nano-carrier modular platform and its construction method and application
WO2020233685A1 (en) * 2019-05-21 2020-11-26 广州市妇女儿童医疗中心 Intein-mediated nano-carrier and application thereof, and nano preparation capable of simultaneously delivering antigen and immunopotentiator
US20230285539A1 (en) * 2020-03-06 2023-09-14 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccines against sars-cov-2 and other coronaviruses
WO2021212230A1 (en) * 2020-04-22 2021-10-28 Medicago I Nc. Suprastructure comprising modified influenza hemagglutinin with reduced interaction with sialic acid
CA3174651A1 (en) 2020-04-30 2021-11-04 Vlp Therapeutics, Inc. Cytokine immunotherapy
WO2021246740A1 (en) 2020-06-01 2021-12-09 (주)인테라 Recombinant expression vector for producing encapsulin-based vaccine, and preparation method therefor
WO2022135563A1 (en) * 2020-12-24 2022-06-30 上海市公共卫生临床中心 Method for simultaneously inducing immune response against multiple viruses
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
WO2022204597A1 (en) * 2021-03-26 2022-09-29 David Weiner Dna encoded nanoparticle vaccine against human papillomavirus, and methods of use thereof
EP4337694A1 (en) 2021-05-12 2024-03-20 Dana-Farber Cancer Institute, Inc. Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
CN115340609B (en) * 2021-05-12 2023-06-13 中国农业科学院兰州兽医研究所 Foot-and-mouth disease virus multi-antigen epitope fusion protein, protein cage nanoparticle and preparation method thereof
EP4380617A1 (en) * 2021-08-06 2024-06-12 Najit Technologies, Inc. Multivalent pan-influenza vaccine
WO2023044388A1 (en) 2021-09-16 2023-03-23 Emergent Product Development Gaithersburg Inc. Vaccine compositions
CN114891121B (en) * 2022-05-11 2024-01-19 天康制药股份有限公司 Bivalent virus-like particle vaccine for resisting PEDV and PRV and preparation method thereof
WO2024167855A1 (en) 2023-02-06 2024-08-15 Emergent Product Development Gaithersburg Inc. Influenza hemagglutinin constructs and compositions
CN116947982B (en) * 2023-07-12 2024-05-14 吉林大学 Three dominant epitope peptide sequences and application thereof in influenza virus vaccine

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337070B1 (en) 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
CA2462455C (en) 2001-10-01 2012-07-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of a preventive vaccine for filovirus infection in primates
US20050108791A1 (en) 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
EP1504037B1 (en) 2002-05-10 2009-12-30 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
GB0319797D0 (en) 2003-08-26 2003-09-24 Leuven K U Res & Dev Particle size reduction of poorly soluble drugs
WO2007032241A1 (en) 2005-09-12 2007-03-22 Japan Science And Technology Agency Microparticle-protein complex, method for production of the complex, semiconductor device, and fluorescent labeling method
AU2007224034B2 (en) 2006-03-07 2012-03-29 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
MX2009007106A (en) 2006-12-29 2010-04-30 Inst Pasteur Of Shanghai Lentivirus pseudotyped with influenza hemagglutinin and methods of use.
EP3040082A1 (en) 2007-05-31 2016-07-06 Statens Serum Institut Influenza vaccines
WO2008157419A2 (en) 2007-06-13 2008-12-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic peptides of influenza virus
EP2190472A2 (en) 2007-08-20 2010-06-02 Fraunhofer USA, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
CA2713879C (en) 2008-02-01 2020-01-07 Alpha-O Peptides Ag Self-assembling peptide nanoparticles useful as vaccines
JP5382489B2 (en) 2008-03-29 2014-01-08 国立大学法人 奈良先端科学技術大学院大学 Circularly polarized light-emitting nanoparticles
US20110177122A1 (en) 2008-09-26 2011-07-21 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Dna prime/activated vaccine boost immunization to influenza virus
AU2010234849B2 (en) 2009-03-30 2017-06-22 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
RU2579903C2 (en) 2009-09-22 2016-04-10 Медикаго Инк. Method of production of virus-like particles of plants
US20120219584A1 (en) 2009-10-05 2012-08-30 The United States Of America As Represented By The Secretary, Department Of Health Protection against pandemic and seasonal strains of influenza
WO2011102900A1 (en) 2010-02-18 2011-08-25 Technovax, Inc. Universal virus-like particle (vlp) influenza vaccines
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
WO2013044203A2 (en) 2011-09-23 2013-03-28 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES Novel influenza hemagglutinin protein-based vaccines
WO2013056122A1 (en) 2011-10-12 2013-04-18 University Of Washington Engineered outer domain (eod) of hv gp120 and mutants thereof
WO2015054639A1 (en) 2013-10-11 2015-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epstein-barr virus vaccines
ES2924721T3 (en) 2014-05-27 2022-10-10 Us Health Influenza stabilized hemagglutinin stem region trimers and uses thereof
EP3177720B1 (en) 2014-08-08 2021-09-22 VLP Therapeutics, Inc. Virus like particle comprising modified envelope protein e3
SG11201705264WA (en) * 2014-12-31 2017-07-28 The Usa As Represented By The Secretary Detp Of Health And Human Services Novel multivalent nanoparticle-based vaccines

Also Published As

Publication number Publication date
JP6957580B2 (en) 2021-11-02
JP7250878B2 (en) 2023-04-03
EP3240567A2 (en) 2017-11-08
US11191727B2 (en) 2021-12-07
WO2016109792A3 (en) 2016-09-01
US20180021258A1 (en) 2018-01-25
IL253187A0 (en) 2017-08-31
IL253187B (en) 2022-07-01
AU2020200303B9 (en) 2022-09-15
US11938221B2 (en) 2024-03-26
WO2016109792A2 (en) 2016-07-07
CN107427571A (en) 2017-12-01
AU2022279441A1 (en) 2023-02-02
AU2020200303B2 (en) 2022-09-08
JP2022023102A (en) 2022-02-07
CA2974346A1 (en) 2016-07-07
JP6655623B2 (en) 2020-02-26
JP2018501801A (en) 2018-01-25
AU2020200303A1 (en) 2020-02-06
AU2015373928A1 (en) 2017-08-10
IL294189A (en) 2022-08-01
US20240226012A1 (en) 2024-07-11
AU2015373928B2 (en) 2019-10-17
US20220054419A1 (en) 2022-02-24
IL294189B1 (en) 2024-08-01
JP2020039347A (en) 2020-03-19
KR102713707B1 (en) 2024-10-04
WO2016109792A8 (en) 2017-07-27
BR112017014219A2 (en) 2018-03-06
KR20170102905A (en) 2017-09-12

Similar Documents

Publication Publication Date Title
IL253187A0 (en) Novel multivalent nanoparticle-based vaccines
GB201410971D0 (en) Vaccine
GB201518684D0 (en) Vaccine
PL3185899T3 (en) Improved hvt-vectored nd-ibd vaccine
IL249823A0 (en) Meningococcus vaccines
GB2534439B (en) Packer
IL248223B (en) Vaccine compositions
AU358070S (en) Airship
AU358065S (en) Airship
IL247159B (en) Pcsk9 vaccines
IL252086A0 (en) Novel methods
IL264605A (en) Multivalent vaccine composition
GB201522132D0 (en) Vaccine
GB201407755D0 (en) Nanocrystals
GB201616904D0 (en) Vaccine
HK1248560A1 (en) Dna-peptide combination vaccine
HK1244824A1 (en) Multivalent ligand-lipid constructs
EP3045216A4 (en) Coupled balloon
GB201608821D0 (en) Vaccines
PT3188755T (en) Vaccine
PL3228650T3 (en) Novel peg derivative
GB201417214D0 (en) Vaccine
GB201419061D0 (en) Conjugated Vaccine
HU4380U (en) Sunshade
GB201614387D0 (en) Improved vaccines